Apixaban 2.5 MG Oral Tablet for Deep Vein Thrombosis (DVT)

Phase-Based Progress Estimates
Deep Vein Thrombosis (DVT)Apixaban 2.5 MG Oral Tablet - Drug
18 - 89
What conditions do you have?

Study Summary

This trial will test whether direct oral anticoagulants are more effective than subcutaneous enoxaparin at preventing blood clots in patients undergoing autologous breast reconstruction.

Eligible Conditions
  • Deep Vein Thrombosis (DVT)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 90-day events

90-day events
Apixaban vs. Enoxaparin - Bleeding event
Apixaban vs. Enoxaparin - Venous Thromboembolism (VTE) event

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

2 Treatment Groups

1 of 2
1 of 2

Active Control

Experimental Treatment

106 Total Participants · 2 Treatment Groups

Primary Treatment: Apixaban 2.5 MG Oral Tablet · No Placebo Group · Phase 1 & 2

Experimental Group · 1 Intervention: Apixaban 2.5 MG Oral Tablet · Intervention Types: Drug
ActiveComparator Group · 1 Intervention: Enoxaparin 40Mg/0.4mL Prefilled Syringe · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 90-day events

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,165 Previous Clinical Trials
35,768,442 Total Patients Enrolled
Arash Momeni, MDPrincipal Investigator - Stanford University
Stanford Hospital
UniforMedical Services University Of The Hlth Sci (Medical School)
David Grant Usaf Medical Center (Residency)
2 Previous Clinical Trials
130 Total Patients Enrolled

Eligibility Criteria

Age 18 - 89 · Female Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The Caprini score of 6 or greater indicates a high risk of venous thromboembolism.
The text is about adult women.
The individual is scheduled to undergo breast reconstruction using a free flap of abdominal muscle and skin.